Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer a certain degree of revenue stability since patients always need their medicines, regardless of the economic situation. And biotech companies' focus on innovation provides us with the potential for significant growth.
Regeneron Pharmaceuticals (REGN +0.45%) is one of these players, and shareholders have reaped the rewards over the past year: The stock climbed more than 40%. The company has 16 approved or authorized products in the U.S. and other countries, and these include treatments in immunology, ophthalmology, and oncology.
Regeneron's earnings have climbed thanks to this portfolio, and the company also has a solid pipeline to support future earnings growth. Today, with $16 billion in cash and trading around 20x earnings, is Regeneron the cheapest big biotech? Let's find out.
Image source: Getty Images.
Regeneron's earnings gains
Regeneron has been around for nearly 40 years, and since that time has innovated across many treatment areas. Its products have helped revenue and net income advance over time; earnings reached a peak a few years ago as sales of Regeneron's coronavirus antibody cocktail soared and as other leading products generated growth.
REGN Revenue (Annual) data by YCharts
In more recent times, Regeneron's top-selling eye drug Eylea has seen sales decrease due to competition -- but there's a silver lining in this dark cloud. The company's Eylea HD, an updated, higher-dose formula, is taking some of that market share and represents a fresh growth driver. Meanwhile, immunology drug Dupixent -- sold in partnership with Sanofi -- and cancer drug Libtayo are also driving gains.
And in the most recent quarter, Regeneron's earnings figures and news suggest a shift into a new wave of growth. The big biotech reported record sales for Libtayo and Eyelea HD, increasing 51% to $550 million and 62% to $699 million, respectively. Sanofi records Dupixent sales, and Regeneron is now bringing in its full share of collaboration profits since it paid off its development balance. Dupixent also delivered record revenue in the quarter.
Speaking of Sanofi, Regeneron and the French pharma company expanded their alliance, with the addition of several Regeneron antibodies to the deal. Regeneron gained an upfront payment of $1 billion and may win as much as $7 billion on the achievement of milestones. Regeneron also shares in the profits from any future products resulting from the collaboration. This should support growth in the coming quarters and further down the road.
50 candidates in the pipeline
Meanwhile, the company's pipeline, with about 50 candidates, represents another source of revenue moving forward. The company has ongoing phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity. Regeneron recently won approval for Pasatru, a treatment for fibrodysplasia ossificans progressiva, a rare connective tissue disorder. If even a handful of Regeneron's current candidates make it to the finish line, the company could deliver earnings growth well into the future.
Now, let's consider whether Regeneron is the cheapest big biotech. Here's a look at valuation compared to others.
REGN PE Ratio data by YCharts
Regeneron, trading at about 21x trailing 12-month earnings, is the cheapest by that measure among biotech giants. I also like the fact that Regeneron's revenue is climbing right now thanks to strong products; in the third quarter, total revenue rose 36% to more than $5 billion. And the company has a full pipeline that should keep earnings marching higher in the years to come. On top of this, with cash and marketable securities of more than $16 billion at the end of the recent quarter, Regeneron has the resources to support pipeline development.
Regeneron has also offered us a sign that it's confident in its business and the future. In the recent quarterly report, the company said it has made $2.3 billion in share repurchases so far this year and maintains a full-year target of $3 billion.
All of this makes this cheap big biotech an excellent buy right now.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Matt Hougan has a positive outlook on Bitcoin and altcoins

Win an iPhone 18 Pro Max on WEEX? 201 Lucky Eggs Explained

Tesla Autopilot Team Veterans Found Simulation Startup Valued at $1 Billion

CoW Swap Launches on Solana, Supporting USDC and Wrapped SOL Exchange

CoW Swap Launches Alpha Version, Supporting USDC and wSOL Exchange
VICE 6 Crypto: Is VICE 6 (VTC) Linked to GTA 6? How to Verify the Token
Is VICE 6 crypto linked to GTA 6? Compare two Solana tokens using VTC, verify their mint and pool addresses, and see what Rockstar has confirmed.
Ethereum Price Near $1,800: What Could Confirm an Ethereum (ETH) Rebound?
Ethereum traded near $1,800 on November 16. See what four-hour spot order flow, futures positioning, and Friday’s ETF flows say about an ETH rebound.
TAO Crypto Price Near $190: Is Bittensor (TAO) Recovering or Just Bouncing?
TAO bounced near $190. Compare spot volume, futures positioning, and Bittensor subnet flows to see what would confirm a more durable recovery.
VVV Crypto: What Is Venice Token, Why Venice Token (VVV) Rose and What DIEM Actually Does
Venice Token rose about 14.6% in one November 15 snapshot. Learn what the data shows, how VVV staking works, and what DIEM’s daily API credit buys.

Why Did Bitcoin (BTC) Drop Below $70,000? What Long Liquidations Tell Us
See why Bitcoin fell below $70,000 on November 13, how long liquidations amplified the decline, and what to watch before calling a rebound. If you already plan to trade, you can check whether your activity qualifies for the WEEX Lucky Eggs event, scheduled to run through November 25, 2026 (UTC+8).

WEEX Lucky Eggs: How to Earn Daily Egg Cracks and Win Every Time
Learn how to earn daily WEEX Lucky Eggs from qualifying futures trading volume, check your progress, and understand what “Win Every Time” means.

Meta’s Internal Prediction App Uses Points, Not Cash — and That Distinction Matters

US Signs Silicon Peace Agreement with Eight Nations

Three Questions Every Investor Should Ask About Any Management Team

NuScale Stock Has Lost More Than Half Its Value in 2026, Its Worst Year Since 2023. Here's What Happened the Year After That One.

From 'Patching' to 'Eliminating Entire Classes of Bugs': How to Build Internet Resilience?

5 Dividend Stocks With High Yields That Are Safer Than You Might Think

MiCA gave crypto a passport, but customers still face borders

Unocoin halts all services after hackers bypass BitGo freeze

Can the Anthropic IPO Save the AI Rally?

Hyperliquid Q3 Revenue Reaches $190.9 Million, Kraken Parent Company Sees 12% Decline in Earnings

Guoyin Financial Leasing Plans to Purchase Computer Equipment for 981 Million Yuan

‘Roadmap is Complete,' Cardano Founder Charles Hoskinson Says

In Anthropic's Doomsday Narrative, There Is No Room for Jensen Huang

What Investment Signals Are Released as the 'Big Three' of AI New Cloud Submit Their Reports?

RWA Weekly: NYSE to Use Avalanche for Settling Tokenized Stocks; Goldman Sachs, Citigroup Commit Approximately $270 Million to Joint Stablecoin Project

BNY Mellon Adds to Invesco Galaxy Bitcoin ETF: What Changes with the Custody Filing?

Ethereum Foundation Launches Universal Ethereum Signer App

CoreWeave Says Its AI Demand Is 10 Times Its Capacity Through 2027. I Think Micron Stock Is Still Worth Buying.

MultiBank Group and Universal Sign Agreement to Develop USDU Settlement Capabilities for Institutional Clients
Matt Hougan has a positive outlook on Bitcoin and altcoins
Win an iPhone 18 Pro Max on WEEX? 201 Lucky Eggs Explained
Tesla Autopilot Team Veterans Found Simulation Startup Valued at $1 Billion
CoW Swap Launches on Solana, Supporting USDC and Wrapped SOL Exchange
CoW Swap Launches Alpha Version, Supporting USDC and wSOL Exchange
VICE 6 Crypto: Is VICE 6 (VTC) Linked to GTA 6? How to Verify the Token
Is VICE 6 crypto linked to GTA 6? Compare two Solana tokens using VTC, verify their mint and pool addresses, and see what Rockstar has confirmed.










